logo

For the Inventor, By the Inventor

Lugano, Switzerland

Federico Mailland

USPTO Granted Patents = 23 

 

 

Average Co-Inventor Count = 1.7

ph-index = 3

Forward Citations = 29(Granted Patents)


Location History:

  • Milan, IT (2005 - 2019)
  • Lugano, CH (2012 - 2019)

Company Filing History:

goldMedal23 out of 29 
 
Polichem S.a.
 patents

Years Active: 2005-2019

Loading Chart...
Loading Chart...
Loading Chart...
23 patents (USPTO):Explore Patents
1. 10201490 - Use of chitosans for the treatment of nail inflammatory diseases (2019-02-12),
2. 10172811 - Topical antifungal composition for treating onychomycosis (2019-01-08),
3. 9446027 - Use of pidotimod to treat irritable bowel syndrome (2016-09-20),
4. 9284306 - (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel (2016-03-15),
5. 9173827 - Use of chitosans to increase nail growth rate (2015-11-03),
6. 9125806 - Compositions with enhanced elasticizing activity (2015-09-08),
7. 9107877 - Method of treating onychomycosis (2015-08-18),
8. 9067927 - (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel (2015-06-30),
9. 9034845 - Compositions for treating rosacea (2015-05-19),
10. 8969380 - Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents (2015-03-03),
11. 8906881 - Use of chitosans for the treatment of nail inflammatory diseases (2014-12-09),
12. 8865201 - Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant in the manufacture of a medicament for treating female genital disorders (2014-10-21),
13. 8729098 - Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof (2014-05-20),
14. 8729076 - Secondary 8-hydroxyquinoline-7-carboxamide derivatives (2014-05-20),
15. 8697753 - Method of treating onychomycosis (2014-04-15),

Title: The Innovative Contributions of Federico Mailland

Introduction: Federico Mailland, an accomplished inventor based in Lugano, Switzerland, has made significant strides in the field of pharmaceuticals with a total of 23 patents to his name. His work primarily revolves around innovative treatments for nail inflammatory disorders and other dermatological conditions.

Latest Patents: Among his latest contributions, Mailland has developed a formulation utilizing chitosans for the treatment of nail inflammatory diseases. This formulation includes chitosan in the form of an amino-polysaccharide derivative and can take the form of nail lacquer, spray, cream, ointment, gel, lotion, or foam. The concentration of chitosan may range from 0.1% to 25% by weight of the total formulation, demonstrating his commitment to creating versatile therapeutic options.

Another notable patent focuses on a topical antifungal composition for treating onychomycosis. This composition comprises terbinafine and/or a pharmaceutically acceptable salt in a concentration of 9% to 11% by weight, alongside hydroxypropyl chitosan and water. With a careful balance of ingredients, it promises a straightforward yet effective solution to a common medical issue.

Career Highlights: Federico Mailland's career is distinguished by his role at Polichem S.A., a company renowned for its dedication to developing innovative pharmaceutical products. His extensive patent portfolio reflects his ability to identify and address unmet medical needs through inventive solutions.

Collaborations: In his endeavors, Mailland collaborates with talented individuals such as Michela Legora and Stefania Gagliardi. Their collaborative efforts contribute to the impactful innovations that emerge from Polichem S.A., highlighting the importance of teamwork in the patent development process.

Conclusion: Federico Mailland stands out as a notable inventor whose work in pharmacology continues to pave the way for innovative treatments in dermatology. With a robust patent portfolio and a collaborative spirit, he exemplifies the essence of creativity and determination in the field of pharmaceutical innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…